Skip to main content

Lemme GLP-1 Daily and Reset: Ingredient Evidence and Cost

By the Peptide Dossier Editorial TeamUpdated How we source

Lemme Reset, previously marketed as GLP-1 Daily, is a plant-extract supplement. The seller expressly says it contains no GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug. Its ingredient studies include genuine positive findings, but those findings should be matched to the studied preparation, population and outcome.

Current formula and price

On October 27, 2026, the official listing gave 200 mgEriomin lemon extract,400 mgMorosil red-orange extract and 176.5 mgSupresa saffron per two-capsule serving, with 30 servings. It listed $80 one-time,$64 monthly subscription,$120 for two bottles or $168 for three. Promotions, delivery charges and renewal conditions can change; no purchase or independent composition test was performed.

Eriomin: promising biomarkers, different from a drug

A randomized crossover study in 30 people with hyperglycemia used 200 mgdaily for 12 weeks per treatment period and reported a 17% GLP-1 increase and 5% glucose reduction among its findings. Original abstract. A separate 103 person randomized study found favorable glycemic markers without anthropometric change. Original parallel-group study. These are ingredient-specific metabolic signals, not a head-to-head test against semaglutide or proof of finished-product weight loss.

Morosil and saffron: retain the positive evidence

A randomized double-blind trial studied 400 mgMorosil with lifestyle measures in overweight adults; the paper describes 180 randomized participants and 44 withdrawals before baseline completion. Its weight/body-composition findings must be read with that attrition and cointervention context. Original trial.

An eight-week trial of 176.5 mgdaily Satiereal saffron in 60 mildly overweight women reported reduced weight and snacking versus placebo. Original abstract. The exact tested extract matters: evidence for one branded ingredient is not automatic proof for a differently named extract or the complete Lemme combination.

What remains unproved about the combination

The reviewed seller page cites studied ingredients. This review did not establish a randomized finished-formula outcome trial, synergy or a drug-like appetite effect. Nor does an absence of such evidence prove every user experiences nothing. Define the outcome you want and ask how the actual formulation was studied before assigning a universal benefit or buying recommendation.

Historical allegations are not a current court finding

A filed 2025 New York complaint, Robins v. Lemme, No.1:25-cv-01938, alleged misleading claims aboutGLP-1 andweightmanagement. Filed complaint copy. It establishes the allegations made, not liability. The current docket status and any later proceedings were not verified here; an old filing should not be labeled a currently pending case or a verdict.

Suitability and value require their own assessment

The product warning asks people who are pregnant, nursing, have conditions, low blood sugar or take medicines to consult a physician. Ingredient tolerability in small short studies does not establish a clean, long-term or universally low-risk safety profile for this formula. Price comparisons with generic extracts or compounded medicine cannot establish equivalence or an appropriate substitute.

Related reading

Frequently Asked Questions

The current seller listing explicitly says Reset contains no GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug. That describes the labeled formulation, not an independent assay.

The listed two-capsule serving containsEriomin 200 mg, Morosil 400 mgandSupresa 176.5 mg. Ingredient studies should be distinguished from a randomized trial of the combined product.

Ingredient studies report some positive metabolic, weight or snacking outcomes, depending on the ingredient and population. A finished-product randomized weight-loss benefit or medication-equivalent effect was not established here.

A filed 2025 Robins complaint challenged the marketing. The complaint contains allegations, not a liability finding; current docket status and later proceedings were not verified in this review.

The current listing shows $80 one-time or $64 monthly subscription, with multi-bottle options. Confirm current checkout, delivery and renewal terms for the selected option.

It is a labeled botanical supplement, not a semaglutide or tirzepatide medicine. Ingredient biomarker findings do not establish equivalent potency, weight loss or safety; compounds also should not inherit branded-drug trial outcomes.

Small ingredient studies and label warnings do not establish universal low risk or a clean safety profile. Discuss the exact formula, medicines and health circumstances with the clinician.

Choose based on the actual goal and evidence for the complete formulation. No broad recommendation for mild metabolic goals or guaranteed blood-sugar/appetite benefit is established.